Enspryng, Tocilizumab for NMOSD Found Safe, Effective in Meta-analysis

Enspryng (satralizumab) and tocilizumab — two interleukin-6 (IL-6) receptor inhibitors that prevent inflammation — are generally safe and effective for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a recent meta-analysis reported. Researchers determined these results by analyzing safety and efficacy outcomes across…

Enspryng for NMOSD Now Available in Taiwan, Chugai Announces

Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…